INSIDE THIS ISSUE
- Large Price Changes
- Reminder – New HCPCS C-Codes Effective April 1, 2018
- Reminder – New HCPCS Q-Codes Effective April 1, 2018
- Reminder – HCPCS Q-Code Description Change Effective April 1, 2018
- Reminder – Deleted HCPCS Q-Code Effective April 1, 2018
- Reminder – Part B Biosimilar Biological Product Payment Effective April 1, 2018
- January 2018 ASP Pricing File Revised
- April 2018 NOC Pricing File – New Drug Added
Drug Reimbursement Code Price Updates
- New/Updated Billing and Clinical Information
Large Price Changes:
We identify and report on the codes with the most substantial pricing increases or decreases each month and detail the rationale for the change.
Of the 60 AWP Drug Code Price changes this month, 20 (33%) were price decreases. The table in the Drug Reimbursement Code Price Updates section includes all AWP drug Code Price changes for this month. See below for examples of codes with significant price changes this month.
J0594 Injection, busulfan, 1 mg
- Decrease of 46% due to decrease for 2 generic NDCs
J1644 Injection, heparin sodium, per 1,000 units
- Decrease of 44% due to 12 new generic NDCs entering market
J0698 Cefotaxime sodium, per gram
- Decrease of 39% due to inactivation of 2 generic NDCs
A9507 Indium In-111 capromab pendetide, diagnostic, per study dose, up to 10 millicuries (Code Price is per 1 vial = 5 millicuries)
- Increase of 100% due to increase by manufacturer
A9540 Technetium Tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries (Code Price is per 1 vial)
- Increase of 50% from due to 1 new NDC added to crosswalk and inactivation of lowest brand NDC
Q9968 Injection, non-radioactive, non-contrast, visualization adjunct (e.g., Methylene Blue, Isosulfan Blue), 1 mg
- Increase of 18% due to increase for 4 generic NDCs
Reminder – New HCPCS Drug C-Codes Effective April 1, 2018:
CMS created 8 new HCPCS drug C-codes effective April 1, 2018 for Medicare’s Hospital OPPS (Outpatient Prospective Payment System) billing. These new codes appear with our April 1, 2018 update. Please note: Brand names, if applicable, are noted in parenthesis and italics if not already noted in the code description.
C9462 Injection, delafloxacin, 1 mg
C9463 Injection, aprepitant, 1 mg
C9464 Injection, rolapitant, 0.5 mg
C9465 Hyaluronan or derivative, Durolane, for intra-articular injection, per dose
C9466 Injection, benralizumab, 1 mg
C9467 Injection, rituximab and hyaluronidase, 10 mg
C9468 Injection, factor IX (antihemophilic factor, recombinant), glycopegylated, Rebinyn, 1 IU
C9469 Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
Reminder – New HCPCS Drug Q-Codes effective April 1, 2018:
CMS created 2 new drug Q-codes to replace Q5102 effective April 1, 2018 (see additional information below). These new codes appear in our April 1, 2018 update.
Q5103 Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg
Q5104 Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg
Reminder – Code Description Change HCPCS Q-Code effective April 1, 2018
CMS has revised the code description for Q5101 to include the trade name of the product effective for April 1, 2018. This revision is due to the new Medicare Part B policy changes for biosimilar biological products (see additional information below).
New Q5101 Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 microgram
Previous: Injection, filgrastim, (G-CSF), biosimilar, 1 microgram
Please note: You will be able to view both the new and previous code descriptions in our April 1, 2018 update. The old code description appears with a strikethrough the HCPCS code.
Reminder – Deleted HCPCS Q-Code effective March 31, 2018
Effective for claims with dates of service on or after April 1, 2018 HCPCS Code Q5102 (which describes both currently available versions of infliximab biosimilars) will be replaced with two new HCPCS codes, Q5103 and Q5104 (see above for details).
Q5102 Injection, infliximab, biosimilar, 10 mg was deleted effective March 31, 2018.
Reminder – Part B Biosimilar Biological Product Payment and Required Modifiers Update for Dates of Service on or after April 1, 2018:
CMS has updated the Medicare Part B policy for biosimilar biological products effective for dates of service on or after April 1, 2018.
Effective January 1, 2018, newly approved biosimilar biological products with a common reference product name will no longer be billable under the same HCPCS code.
Effective for claims with dates of service on or after April 1, 2018, HCPCS code Q5102 (see code description above) was replaced with two new HCPCS Q-codes, Q5103 and Q5104 (see code descriptions above). Also, beginning on April 1, 2018 the use of modifiers that describe the manufacturer of a biosimilar (eg., ZA, ZB and ZC) are no longer required on biosimilar HCPCS codes for Medicare claims.
Please note: The biosimilar modifier requirement for HCPCS code Q5102 was deleted effective March 31, 2018.
Please click on the link for full details regarding the new policy https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/Part-B-Biosimilar-Biological-Product-Payment.html
January 2018 Quarterly ASP (Average Sales Price) Pricing File Revised:
CMS has made revisions to the January 2018 Quarterly ASP pricing file for certain HCPCS codes. The revised payment rates which are effective retroactively to the beginning of the quarter are provided below.
Revised ASP payment rates effective January 1, 2018 through March 31, 2018
J0636: previous rate $0.530, revised payment rate $0.605
J1626: previous rate $0.317, revised payment rate $0.298
J1956: previous rate $1.816, revised payment rate $1.353
J2360: previous rate $7.810, revised payment rate $6.533
J3489: previous rate $13.021, revised payment rate $12.854
J7510: previous rate $0.088, revised payment rate $0.079
J7612: previous rate $0.190, revised payment rate $0.177
J7682: previous rate $39.702, revised payment rate $39.574
As per CMS, “the payment amounts in the quarterly ASP files are 106 percent of the Average Sales Price (ASP) calculated from data submitted by drug manufacturers. The quarter to quarter price changes are generally the result of updated data from the manufacturers of these drugs.”
Our data files and website have incorporated these changes. As a reminder, we display the most recent revised rate on the Medicare Allowable tab on the pricing screen. To view previous Medicare Allowable rates for a quarter (if revised), click on the appropriate Effective Date on the same screen. Please Note: ASP rate revisions are retroactive to the beginning of the quarter.
April 2018 NOC (Not Otherwise Classified) Pricing file – New Drug Added:
CMS released the April 1, 2018 NOC Pricing file with one new product added effective April 1, 2018.
New product added effective April 1, 2018:
- Puraply AM – $111.670 per 1 SQ CM
To view the NOC pricing file on the website, search on a NOC (Not Otherwise Classified) code, product or NDC and click on the link “Listing of CMS ASP+6% rates for NOCs” under Additional Information on the left side of the screen.
DRUG REIMBURSEMENT CODE PRICE UPDATES
This month, during our review of the 2990 Reimbursement HCPCS/CPT® Codes in our system, we identified 60 Drug Codes that required a recalculation of their AWP Code Price. Log in to www.DrugCodeLookUp.com to view the pricing updates for these codes.
DRUGS/DEVICES: NEW/UPDATED BILLING & CLINICAL INFORMATION
As new drugs come to market we review them for possible inclusion in our database. When a new drug is added to the database, we develop detailed clinical and billing information for the drug if appropriate.
During the past month, our review identified two new drugs which needed to be added to our database. Our review of existing drugs in our database with clinical and billing information already assigned identified five drugs that required updating
MAKENA® (hydroxyprgesterone caproate injection) for SUBCUTANEOUS Use – by AMAG Pharmaceuticals, Inc.
TROGARZO™ (ibalizumab-uiyk) injection, for intravenous use – by TheraTechnologies, Inc.
IMBRUVICA® (ibrutinib) capsules/tablets, for oral use – by Pharmacyclics, Inc.
- Indications & Usage, Dosage & Administration, Warnings & Precautions and ICD-10-CM Codes
PURIXAN® (mercaptopurine) oral suspension – by Rare Disease Therapeutics, Inc
- Dosage & Administration and Warnings & Precautions
TASIGNA® (nilotinib) capsules, for oral use – by Novartis
- Indications & Usage, Dosage & Administration and Warnings & Precautions
VERZENIO™ (abemaciclib) tablets, for oral use – by Lilly
- Indications & Usage, Dosage & Administration and Warnings & Precautions
ZINBRYTA™ (daclizumab) injection, for subcutaneous use – by Biogen and Abbvie
- Voluntary withdrawal from U.S. Market notice
Please let us know if you have any questions about the content or functionality of our site. Contact us to request the addition of a code to the site or share your suggestions for enhancements.
2018 RJ Health Systems International, LLC. All rights reserved. This newsletter and its contents are copyright protected. No part of this newsletter may be reproduced in any manner by any means without written permission of RJ Health Systems International, LLC.
CPT copyright 2018 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.